Loading
Major Depression Disorder / TMS · Interventional Study
ClinicalTrials.gov · September 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an active, ongoing single-arm biomarker discovery study in treatment-resistant depression patients undergoing TMS. The study is designed to identify proteomic and metabolomic signatures that distinguish treatment responders from non-responders, but no results have been posted to the registry and no efficacy or safety data are available for interpretation.
Interventional, Single Group, Open label, Diagnostic purpose. Major Depression Disorder; age from 18 Years; to 65 Years; accepts healthy volunteers. Intervention: Transcranial Magnetic Stimualtion Treatment Arm. n = 55. 2 sites: Turkey (Türkiye).
This is an active, ongoing single-arm biomarker discovery study in treatment-resistant depression patients undergoing TMS. The study is designed to identify proteomic and metabolomic signatures that distinguish treatment responders from non-responders, but no results have been posted to the registry and no efficacy or safety data are available for interpretation.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is an active, unblinded, single-arm biomarker discovery study with no results yet reported; it aims to identify proteomic and metabolomic signatures of TMS response but has not yet yielded outcome data.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07039370). This is a study registration, not published results. Lead sponsor: Gulhane Training and Research Hospital. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 55 participants (ESTIMATED). Conditions: Major Depression Disorder. Interventions: DEVICE: TMS. Primary outcome measures: Plasma Proteomic Profile Changes After TMS in Patients with Treatment-Resistant Depression , From enrollment to end of treatment at 4 weeks; Plasma Metabolomic Profile Changes After TMS in Patients with Treatment-Resistant Depression , From enrollment to end of treatment at 4 weeks; Fold Change in Baseline Proteomic Markers Between Treatment Responders and Non-Responders , From enrollment to end of the treatment at 4 weeks; Variable Importance in Projection Scores of Predictive Proteins , Baseline and End of 4-week treatment; Area Under the ROC Curve for Predictive Proteomic Markers Between Treatment Responders and Non-Responders , Baseline and End of 4-week treatment; Fold Change in Baseline Plasma Metabolomic Markers Between TMS Responders and Non-Responders , Baseline; Variable Importance in Projection Scores of Baseline Plasma Metabolomic Markers Between TMS Responders and Non-Responders , Baseline and End of 4-week treatment; Area Under the ROC Curve of Baseline Plasma Metabolomic Markers Between TMS Responders and Non-Responders , Baseline and End of 4-week treatment. Brief summary: Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option for treatment-resistant depression (TRD). This study aims to identify biomarkers that predict TMS treatment response in TRD, provide insights into the neurobiological mechanisms underlying TMS efficacy, and contribute to personalized treatment strategies. By establishing proteomic and metabolomic signatures, this research seeks to enhance clinical decision-making, reduce healthcare costs, and improve patient outcomes in TRD. The findings will align with the precision medicine movement in psychiatry, advancing biomarker-driven therapeutic approaches for treatment-resistant depression.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.